Related Experiment Videos
Quinupristin/dalfopristin: spectrum of activity, pharmacokinetics, and initial clinical experience
1Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada.
Abstract:
In recent years, the prevalence of multiple drug-resistant strains of common Gram-positive pathogens has grown in many regions of the world. Increasingly, methicillin-resistant Staphylococcus aureus, coagulase-negative staphylococci, vancomycin-resistant enterococci, and penicillin-resistant pneumococci have been identified as causative organisms in serious and life-threatening infections. This increase in resistance highlights the need for new antimicrobial agents to expand the therapeutic armamentarium. Quinupristin/dalfopristin is the first of a unique class of antibiotics called streptogramins. It is characterized by a unique mechanism of action, intracellular activity, synergistic activity of its components, broad spectrum of activity against most Gram-positive cocci, common respiratory pathogens, and anaerobes, and demonstrated postantibiotic effect. Clinical evidence to date indicates that quinupristin/dalfopristin may be effective for the treatment of multidrug-resistant infections, especially those due to vancomycin-resistant enterococci and methicillin-resistant staphylococci. This article reviews the pharmacology, microbiology, and clinical experience with quinupristin/dalfopristin to date.
Insights
The rise of drug-resistant bacteria necessitates new treatments. Quinupristin/dalfopristin, a novel streptogramin antibiotic, shows promise for treating serious infections caused by resistant Gram-positive pathogens.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Increasing prevalence of multidrug-resistant Gram-positive pathogens globally.
- Identification of resistant strains like MRSA, VRE, and penicillin-resistant pneumococci in severe infections.
- Urgent need for novel antimicrobial agents to combat rising resistance.
Purpose of the Study:
- To review the pharmacology, microbiology, and clinical experience of quinupristin/dalfopristin.
- To assess the potential of quinupristin/dalfopristin as a treatment for multidrug-resistant infections.
Main Methods:
- Review of existing literature on quinupristin/dalfopristin.
- Analysis of its mechanism of action, spectrum of activity, and clinical efficacy.
Main Results:
- Quinupristin/dalfopristin is a novel streptogramin antibiotic with a unique mechanism of action.
- Demonstrates broad-spectrum activity against Gram-positive cocci, respiratory pathogens, and anaerobes.
- Shows potential efficacy against vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus.
Conclusions:
- Quinupristin/dalfopristin represents a significant addition to the therapeutic options for multidrug-resistant infections.
- Its unique properties and demonstrated clinical activity support its use in specific challenging infections.
- Further clinical experience will continue to define its role in combating resistant pathogens.